HRP20180687T1 - Kompozicije i metode za liječenje celijakije spru - Google Patents

Kompozicije i metode za liječenje celijakije spru

Info

Publication number
HRP20180687T1
HRP20180687T1 HRP20180687TT HRP20180687T HRP20180687T1 HR P20180687 T1 HRP20180687 T1 HR P20180687T1 HR P20180687T T HRP20180687T T HR P20180687TT HR P20180687 T HRP20180687 T HR P20180687T HR P20180687 T1 HRP20180687 T1 HR P20180687T1
Authority
HR
Croatia
Prior art keywords
celiacia
spru
compositions
treatment
methods
Prior art date
Application number
HRP20180687TT
Other languages
English (en)
Croatian (hr)
Inventor
Justin Siegel
David Baker
Sydney Rin Anna Gordon
Ingrid Swanson Pultz
Elizabeth Joy Stanley
Sarah Jane Wolf
Original Assignee
University Of Washington Through Its Center For Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington Through Its Center For Commercialization filed Critical University Of Washington Through Its Center For Commercialization
Publication of HRP20180687T1 publication Critical patent/HRP20180687T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
HRP20180687TT 2011-08-10 2012-08-10 Kompozicije i metode za liječenje celijakije spru HRP20180687T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161521899P 2011-08-10 2011-08-10
EP12748354.3A EP2718434B1 (en) 2011-08-10 2012-08-10 Compositions and methods for treating celiac sprue disease
PCT/US2012/050364 WO2013023151A2 (en) 2011-08-10 2012-08-10 Compositions and methods for treating celiac sprue disease

Publications (1)

Publication Number Publication Date
HRP20180687T1 true HRP20180687T1 (hr) 2018-06-15

Family

ID=46690751

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180687TT HRP20180687T1 (hr) 2011-08-10 2012-08-10 Kompozicije i metode za liječenje celijakije spru

Country Status (18)

Country Link
US (7) US9289473B2 (enExample)
EP (3) EP4023243A3 (enExample)
JP (5) JP6342802B2 (enExample)
CA (1) CA2882502A1 (enExample)
CY (1) CY1120877T1 (enExample)
DK (1) DK2718434T3 (enExample)
ES (2) ES2896489T3 (enExample)
HR (1) HRP20180687T1 (enExample)
HU (1) HUE037870T2 (enExample)
LT (1) LT2718434T (enExample)
NO (1) NO2718434T3 (enExample)
PL (2) PL2718434T3 (enExample)
PT (1) PT2718434T (enExample)
RS (1) RS57234B1 (enExample)
SI (1) SI2718434T1 (enExample)
SM (1) SMT201800249T1 (enExample)
TR (1) TR201806885T4 (enExample)
WO (1) WO2013023151A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289473B2 (en) 2011-08-10 2016-03-22 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
ES2702907T3 (es) 2013-08-14 2019-03-06 Univ Washington Through Its Center For Commercialization Composiciones para tratar la enfermedad de esprúe celíaco
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
MX392140B (es) 2015-06-08 2025-03-21 Univ Washington Composiciones y uso de las mismas para tratar la enfermedad celiaca.
AU2017380106B2 (en) * 2016-12-22 2024-05-09 Ew Nutrition Gmbh Stable protease variants
WO2020087017A1 (en) * 2018-10-26 2020-04-30 The Regents Of The University Of California Use of proteolytic enzymes to enhance protein bioavailability
US20240226248A9 (en) * 2018-10-26 2024-07-11 The Regents Of The University Of California Methods and compositions for improving protein hydrolysis
US20250064903A1 (en) 2020-10-30 2025-02-27 University Of Washington Compositions and methods for treating celiac sprue disease
CN119136820A (zh) 2022-01-26 2024-12-13 迪杰斯蒂维公司 稳定血液葡萄糖的方法和组合物
WO2025068987A1 (en) 2023-09-28 2025-04-03 Takeda Pharmaceutical Company Limited A method of producing a kumamolisin-as polypeptide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688229B1 (fr) 1992-03-09 1995-06-23 Ulice Soc Procede de synthese enzymatique d'esters alkyliques de peptides, produits ainsi obtenus et utilisation desdits produits.
JP2002078489A (ja) * 2000-09-04 2002-03-19 Daiwa Kasei Kk セリン残基が活性発現に関与する新規酸性プロテアーゼ
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
EP1572127B2 (en) 2002-02-14 2014-10-29 The Board of Trustees of the Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7265093B2 (en) 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
WO2003096984A2 (en) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
DK1563300T3 (da) 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostisk fremgangsmåde til cøliaki
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
EP1600141B1 (en) 2004-05-24 2013-04-17 3M Deutschland GmbH Collagenolytic active enzyme containing compositions for the treatment of dental caries
EP1726643A1 (en) * 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
JP2012500263A (ja) 2008-08-21 2012-01-05 アルヴィン ファーマシューティカルズ インコーポレーティッド タンパク質の経口投与のための製剤
US9289473B2 (en) 2011-08-10 2016-03-22 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
CA2852365C (en) 2011-12-06 2021-01-26 Fondazione Istituto Insubrico Di Ricerca Per La Vita Proteases able to hydrolyze gluten peptides and proteins at acidic ph, from the actinomycete actinoallomurus.
ES2702907T3 (es) 2013-08-14 2019-03-06 Univ Washington Through Its Center For Commercialization Composiciones para tratar la enfermedad de esprúe celíaco

Also Published As

Publication number Publication date
US20160166656A1 (en) 2016-06-16
TR201806885T4 (tr) 2018-06-21
JP2021094031A (ja) 2021-06-24
EP2718434A2 (en) 2014-04-16
ES2667418T3 (es) 2018-05-10
US20170296633A1 (en) 2017-10-19
SI2718434T1 (en) 2018-06-29
JP2014529399A (ja) 2014-11-13
EP2718434B1 (en) 2018-03-28
JP2017221201A (ja) 2017-12-21
US20240207376A1 (en) 2024-06-27
US20190083585A1 (en) 2019-03-21
WO2013023151A2 (en) 2013-02-14
SMT201800249T1 (it) 2018-07-17
US10874720B2 (en) 2020-12-29
JP6342802B2 (ja) 2018-06-13
LT2718434T (lt) 2018-08-10
PL3400958T3 (pl) 2022-01-03
WO2013023151A3 (en) 2013-07-18
JP6502428B2 (ja) 2019-04-17
EP4023243A2 (en) 2022-07-06
EP3400958A1 (en) 2018-11-14
US20210085761A1 (en) 2021-03-25
DK2718434T3 (en) 2018-07-09
PT2718434T (pt) 2018-05-21
ES2896489T3 (es) 2022-02-24
HUE037870T2 (hu) 2018-09-28
EP3400958B1 (en) 2021-08-04
US9925249B2 (en) 2018-03-27
NO2718434T3 (enExample) 2018-08-25
US10149892B2 (en) 2018-12-11
US20180185458A1 (en) 2018-07-05
US9707280B2 (en) 2017-07-18
CY1120877T1 (el) 2019-12-11
JP2024028452A (ja) 2024-03-04
US20140178355A1 (en) 2014-06-26
RS57234B1 (sr) 2018-07-31
CA2882502A1 (en) 2013-02-14
PL2718434T3 (pl) 2018-08-31
US9289473B2 (en) 2016-03-22
JP2019162107A (ja) 2019-09-26
EP4023243A3 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
HRP20180237T1 (hr) Metode za liječenje hcv-a
EP2787985A4 (en) BIOCIDAL COMPOSITION AND METHODS OF USE
PL3199024T3 (pl) Zastosowanie kompozycji cyklodekstryny i stosowne sposoby
BR112013024401A2 (pt) métodos e composições para o tratamento do transtorno do déficit de atenção
LT2885010T (lt) Tautopatijos gydymo būdai
EP2670434A4 (en) TREATMENT OF TAUOPATHIES
DK3444342T3 (da) Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
HRP20180687T1 (hr) Kompozicije i metode za liječenje celijakije spru
EP2756740A4 (en) COLD PLASMA PROCESSING DEVICES AND ASSOCIATED METHODS
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
EP2836482A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
PL2704737T3 (pl) Terapeutyczne kompozycje nukleaz i sposoby
HUE053247T2 (hu) Mieloszuppresszió kezelése
BR112014006291A2 (pt) composição e utilização da composição
ZA201408056B (en) Compositions and methods for the treatment of mucositis
EP2785823A4 (en) CLEANING COMPOSITIONS AND METHODS
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
EP2718277A4 (en) METHOD AND COMPOSITIONS FOR TREATING MITOCHONDRIAL TOXICITY
DK2661274T3 (da) Sammensætninger og fremgangsmåder med aloepolysaccharider
EP2637505A4 (en) COMPOSITIONS AND METHOD FOR TREATING EFFECTIVE DYSFUNCTION
IL231907B (en) Compounds and compositions for treatment of transthyretin-associated amyloidosis